Evidence map›Paper›PMID 31986488›Full record

ArticleAging2020

TPGS-1000 exhibits potent anticancer activity for hepatocellular carcinoma

Yidan Chen, Liqin Mo, Xuan Wang, Bi Chen, Yunfen Hua, Linyan Gong, Fei Yang, Yongqiang Li, Fangfang Chen, Guiting Zhu and 9 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Yidan ChenCancer Research Institute, Hangzhou Cancer Hospital, Zhejiang, China.
Liqin MoCancer Research Institute, Hangzhou Cancer Hospital, Zhejiang, China.
Xuan WangLife Sciences Research Institute, College of Life and Environmental Sciences, Hangzhou Normal University, Zhejiang, China.
Bi ChenOncology Department, The Affiliated Hospital of Hangzhou Normal University, Zhejiang, China.
Yunfen HuaCollege of Pharmaceutical Science, Zhejiang University of Technology, Zhejiang, China.
Linyan GongOncology Department, The Affiliated Hospital of Hangzhou Normal University, Zhejiang, China.
Fei YangOncology Department, The Affiliated Hospital of Hangzhou Normal University, Zhejiang, China.
Yongqiang LiOncology Department, The Affiliated Hospital of Hangzhou Normal University, Zhejiang, China.
Fangfang ChenOncology Department, The Affiliated Hospital of Hangzhou Normal University, Zhejiang, China.
Guiting ZhuOncology Department, The Affiliated Hospital of Hangzhou Normal University, Zhejiang, China.
Wei NiOncology Department, The Affiliated Hospital of Hangzhou Normal University, Zhejiang, China.
Cheng ZhangOncology Department, The Affiliated Hospital of Hangzhou Normal University, Zhejiang, China.
Yuming ChengOncology Department, The Affiliated Hospital of Hangzhou Normal University, Zhejiang, China.
Yan LuoOncology Department, The Affiliated Hospital of Hangzhou Normal University, Zhejiang, China.
Junping ShiOncology Department, The Affiliated Hospital of Hangzhou Normal University, Zhejiang, China.
Mengsheng QiuLife Sciences Research Institute, College of Life and Environmental Sciences, Hangzhou Normal University, Zhejiang, China.
Shixiu WuCancer Research Institute, Hangzhou Cancer Hospital, Zhejiang, China.
Zhou TanLife Sciences Research Institute, College of Life and Environmental Sciences, Hangzhou Normal University, Zhejiang, China.
Kaifeng WangCancer Research Institute, Hangzhou Cancer Hospital, Zhejiang, China.
Affiliated Hospital of Hangzhou Normal University · CNHangzhou Cancer Hospital · CNHangzhou Normal University · CNState Key Laboratory of Oncogene and Related Genes · CNZhejiang University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS1000) is the most active water-soluble derivative of vitamin E and has been widely used as a carrier of solvents, plasticizers, emulsifiers, absorbent agents and refractory drug delivery systems. However, its anti-hepatocellular carcinoma (HCC) properties have not been explored. HCC cells were treated with different concentrations of TPGS1000. Cell survival was tested by CCK8 assay, and cell migration was tested by wound healing and Transwell assay. EdU staining verified cell proliferation, and signalling pathway was assayed by Western blot analysis. The BALB/c-nu mouse xenograft model was established to test HCC cell growth

Indexed as

AnimalsAntineoplastic AgentsApoptosisCell Cycle CheckpointsCell Line, TumorCell MovementCell ProliferationCell SurvivalDisease Models, AnimalDNA ReplicationForkhead Box Protein M1HumansMembrane Potential, MitochondrialMiceReactive Oxygen SpeciesSignal TransductionAntineoplastic AgentsForkhead Box Protein M1Reactive Oxygen SpeciesVitamin Eapoptosishepatocellular carcinomamalignancymigrationTPGS1000

Identifiers

PMID31986488
PMCPMC7053644
OpenAlexW3004201777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.